- Home
- SIGA vs PSNL Comparison
SIGA vs PSNL Comparison
Compare SIGA & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIGA
- PSNL
- Stock Information
- Founded
- SIGA 1995
- PSNL 2011
- Country
- SIGA United States
- PSNL United States
- Employees
- SIGA N/A
- PSNL N/A
- Industry
- SIGA Biotechnology: Pharmaceutical Preparations
- PSNL Medical Specialities
- Sector
- SIGA Health Care
- PSNL Health Care
- Exchange
- SIGA Nasdaq
- PSNL Nasdaq
- Market Cap
- SIGA 515.1M
- PSNL 518.8M
- IPO Year
- SIGA 1997
- PSNL 2019
- Fundamental
- Price
- SIGA $8.87
- PSNL $5.82
- Analyst Decision
- SIGA
- PSNL Strong Buy
- Analyst Count
- SIGA 0
- PSNL 4
- Target Price
- SIGA N/A
- PSNL $8.13
- AVG Volume (30 Days)
- SIGA 506.6K
- PSNL 824.9K
- Earning Date
- SIGA 11-06-2025
- PSNL 11-05-2025
- Dividend Yield
- SIGA 6.77%
- PSNL N/A
- EPS Growth
- SIGA N/A
- PSNL N/A
- EPS
- SIGA 1.14
- PSNL N/A
- Revenue
- SIGA $179,639,422.00
- PSNL $80,317,000.00
- Revenue This Year
- SIGA N/A
- PSNL N/A
- Revenue Next Year
- SIGA $115.06
- PSNL $29.83
- P/E Ratio
- SIGA $7.78
- PSNL N/A
- Revenue Growth
- SIGA 3.86
- PSNL 0.36
- 52 Week Low
- SIGA $4.95
- PSNL $2.83
- 52 Week High
- SIGA $9.62
- PSNL $7.79
- Technical
- Relative Strength Index (RSI)
- SIGA 56.96
- PSNL 60.46
- Support Level
- SIGA $8.56
- PSNL $5.48
- Resistance Level
- SIGA $9.16
- PSNL $6.26
- Average True Range (ATR)
- SIGA 0.31
- PSNL 0.33
- MACD
- SIGA -0.03
- PSNL 0.11
- Stochastic Oscillator
- SIGA 68.82
- PSNL 72.86
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.